Ready-made stem cell therapies for pets could be coming
San Diego-based startup Gallant has recently secured a substantial $18 million in Series B funding, propelling its mission to introduce the first FDA-approved, ready-to-use stem cell therapy into veterinary medicine. This significant investment could herald a transformative new approach to treating beloved companion animals, offering renewed hope for pets suffering from chronic conditions.
While stem cell research for human applications has spanned decades, its use in veterinary science remains an experimental yet highly promising field. Gallant, a company established seven years ago, is initially targeting Feline Chronic Gingivostomatitis (FCGS), a painful mouth condition prevalent in cats. The company anticipates receiving FDA approval for this specific therapy as early as 2026, marking a pivotal moment for feline health.
Early results from stem cell treatments have shown encouraging signs in the animal kingdom. Studies involving dogs afflicted with arthritis have demonstrated notable improvements in pain management and mobility, with some benefits extending up to two years. However, research into similar treatments for kidney disease in cats, another area Gallant aims to address, has yielded more varied outcomes, highlighting the complexities and ongoing need for further investigation in this nascent field.
Gallant’s innovative approach distinguishes itself through its remarkable convenience. Unlike most existing stem cell therapies that necessitate harvesting cells directly from the patient or a tissue-matched donor, Gallant’s method utilizes ready-to-use cells derived from donor animals. This groundbreaking allogeneic approach even allows for the use of cells from different species, streamlining the treatment process and making it more accessible for veterinarians and pet owners alike.
The clear potential of Gallant’s pioneering work has resonated deeply with investors. The recent funding round was spearheaded by existing backer Digitalis Ventures, with key participation from NovaQuest Capital Management. Notably, NovaQuest Capital Management previously invested in the first FDA-approved human stem cell therapy, underscoring their confidence in Gallant’s trajectory and its capacity to revolutionize pet healthcare.
Gallant’s journey is rooted in an interesting backstory. The company was founded by Aaron Hirschhorn, who previously achieved success by selling his dog-sitting marketplace, DogVacay, to its primary competitor, Rover. Tragically, Hirschhorn passed away in 2021. Today, Gallant is capably led by Linda Black, who joined the company as its president and chief scientific officer near its inception. To date, Gallant has amassed a total of at least $44 million in funding from investors, reinforcing its position at the forefront of veterinary regenerative medicine.
